However, in transformed tumor cells, Xist appears to have a role in helping to maintain CSCs as histone deacetylase inhibitor (HDACi) Abexinostat induces the differentiation of CSCs in breast cancer with low Xist expression, and Xist has been identified as a biomarker for predicting the response to HDACi [61]. This evidence concerns the gene XIST and breast cancer.